APA (7th ed.) Citation

MR, H., CH, L., SY, J., HY, Y., NR, L., JY, K., . . . EK, S. (2025). Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient. Archive of clinical cases, 12(1), 17. https://doi.org/10.22551/2025.46.1201.10306

Chicago Style (17th ed.) Citation

MR, Han, Lee CH, Jeon SY, Yhim HY, Lee NR, Kwak JY, Park HS, and Song EK. "Pembrolizumab-induced Simultaneous and Multiple Immune-related Adverse Events Including Myasthenia Gravis, Myositis, Hepatitis, and Pityriasis Lichenoides in a Non-small Cell Lung Cancer Patient." Archive of Clinical Cases 12, no. 1 (2025): 17. https://doi.org/10.22551/2025.46.1201.10306.

MLA (9th ed.) Citation

MR, Han, et al. "Pembrolizumab-induced Simultaneous and Multiple Immune-related Adverse Events Including Myasthenia Gravis, Myositis, Hepatitis, and Pityriasis Lichenoides in a Non-small Cell Lung Cancer Patient." Archive of Clinical Cases, vol. 12, no. 1, 2025, p. 17, https://doi.org/10.22551/2025.46.1201.10306.